Try our beta test site
Trial record 8 of 18 for:    duchenne netherlands belgium

A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids (SIDEROS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Santhera Pharmaceuticals
Information provided by (Responsible Party):
Santhera Pharmaceuticals Identifier:
First received: June 17, 2016
Last updated: January 16, 2017
Last verified: January 2017
The purpose of the study is to assess the efficacy of idebenone in delaying the loss of respiratory function in patients with DMD receiving concomitant glucocorticoid steroids

Condition Intervention Phase
Duchenne Muscular Dystrophy (DMD)
Drug: Idebenone 150 mg film-coated tablets
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids

Resource links provided by NLM:

Further study details as provided by Santhera Pharmaceuticals:

Primary Outcome Measures:
  • Change From Baseline in Forced Vital Capacity percent predicted (FVC %p) at Week 78 [ Time Frame: 78 weeks ]
    Delaying the loss of respiratory function in patients with DMD receiving glucocorticoid steroids as measured by changes in FVC %p from Baseline to Week 78 using hospital based spirometry.

Secondary Outcome Measures:
  • Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF %p) at Week 78 [ Time Frame: 78 weeks ]

    Delaying the loss of respiratory function in patients with DMD receiving glucocorticoid steroids as measured by:

    •The change from Baseline to Week 78 in PEF %p assessed by hospital-based spirometry measurements

  • Change From Baseline in Forced Vital Capacity (FVC) at Week 78 [ Time Frame: 78 weeks ]

    Delaying the loss of respiratory function in patients with DMD receiving glucocorticoid steroids as measured by:

    •The time to first 10% decline in FVC (L) during the 78-week treatment period, assessed by hospital-based spirometry measurements

  • Change from Baseline in Inspiratory Flow Reserve (IFR) at Week 78 [ Time Frame: 78 weeks ]

    Delaying the loss of respiratory function in patients with DMD receiving glucocorticoid steroids as measured by:

    •The change from Baseline to Week 78 in IFR assessed by hospital-based spirometry measurements

Estimated Enrollment: 266
Study Start Date: September 2016
Estimated Study Completion Date: August 2019
Estimated Primary Completion Date: July 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: idebenone 150 mg film-coated tablets
900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
Drug: Idebenone 150 mg film-coated tablets
Placebo Comparator: placebo
matching placebo tablets
Drug: placebo

Detailed Description:

The SIDEROS trial is a randomized, placebo controlled, parallel group study of the efficacy of idebenone in delaying the loss of respiratory function, whilst also monitoring safety and tolerability of idebenone in at least 266 DMD patients taking stable dose of concomitant glucocorticoid steroids.

The study treatment period will be 18 months/ 78 weeks and the idebenone dose will be 900 mg/day. Participants can use deflazacort or prednisolone and be on any dose regimen.

Since glucocorticoid steroids are widely used in ambulant boys from an early age until late into teenage and even adult years, this study will not take age and ambulatory status into account and will only exclude patients that need daytime ventilator assistance.

The schedule of assessments will include a Screening Visit and up to 9 protocol visits, including a Follow-up Visit.

A Screening Visit will take place a maximum of 6 weeks prior to the Baseline Visit (Visit 1, study day -1). Beginning at Baseline, the patient will receive study medication to be taken at home, and will undergo regular assessments in the clinic throughout the study period until Visit 8 at Week 78 at which time the study will be completed and medication discontinued.

All patients completing Visit 8/Week 78, and considered eligible by the Investigator will be able to participate in an open-label extension study (SIDEROS-E) and will continue to receive idebenone until the SIDEROS-E is terminated or Marketing Authorization is obtained for idebenone in DMD, whichever occurs first. The duration of the SIDEROS-E study will be defined in a separate protocol.

For all patients not participating in the extension study (SIDEROS-E), a Follow-up Visit (Visit 9/Follow-up Visit) will take place 4 weeks after end of Treatment at Visit 8/Week 78 or after premature discontinuation of study medication.

Each hospital visit will include efficacy assessments (respiratory function assessed by hospital-based spirometry, oxygen saturation, end-tidal CO2) and safety assessments (adverse events, concomitant medication, physical examination, vital signs, safety laboratory evaluations). In addition, respiratory function will be assessed weekly at home with a hand-held device in order to closely monitor respiratory function between hospital visits.

The study medication, all medical procedures and laboratory testing, and the visits to the study centre are free of charge. In addition the patients will receive a travel allowance to cover reasonable expenses to and from the study centre. Participants will not otherwise be compensated for this study.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male patients with a 30% ≤ FVC ≤ 80% of predicted value at Screening and at Baseline.
  2. Minimum 10 years old at Screening
  3. Signed and dated Informed Consent Form.
  4. Documented diagnosis of DMD (severe dystrophinopathy) and clinical features consistent of typical DMD at diagnosis. DMD should be confirmed by mutation analysis in the dystrophin gene or by substantially reduced levels of dystrophin protein (i.e. absent or <5% of normal) on Western blot or immunostaining.
  5. Chronic use of systemic glucocorticoid steroids for DMD related conditions continuously for at least 12 months prior to Baseline without any dose adjustments on a mg/kg basis in the last 6 months (only dose adjustment determined by weight changes are allowed).
  6. Ability to provide reliable and reproducible repeat FVC within 15% of the screening assessment at Baseline.
  7. Patients assessed by the Investigator as willing and able to comply with the requirements of the study, possess the required cognitive abilities and are able to swallow study medication.
  8. Patients who have been immunized with 23-valent pneumococcal polysaccharide vaccine or any other pneumococcal polysaccharide vaccine as per national recommendations, as well as annually immunized with inactivated influenza vaccine.

Exclusion Criteria:

  1. Symptomatic heart failure (defined as Stage C by ACCF/AHA guideline or NYHA III-IV) and/or symptomatic ventricular arrhythmias.
  2. Ongoing participation in any other therapeutic trial and/or intake of any investigational drug within 90 days prior to Baseline (only exception allowed is use of Deflazacort in US as part of the Expanded Access Program).
  3. Prior or ongoing exon-skipping or read-through therapy for DMD.
  4. Planned or expected spinal fixation surgery during the study period (as judged by the Investigator, i.e. due to rapidly progressing scoliosis), prior spinal fixation surgery is allowed if it took place more than 6 months prior to Screening.
  5. Asthma, bronchitis/COPD, bronchiectasis, emphysema, pneumonia or presence of any other non-DMD respiratory illness that affects respiratory function.
  6. Chronic use of beta2-agonists or any use of other bronchodilating/bronchoconstricting medication (inhaled steroids, sympathomimetics, anti-cholinergics, antihistamines); chronic use is defined as a daily intake for more than 14 days.
  7. Any bronchopulmonary illness that required treatment with antibiotics within 3 months prior to Screening.
  8. Moderate or severe hepatic impairment (Child-Pugh class B [7 to 9 points] or Child-Pugh class C [10 to 15 points]) or severe renal impairment (eGFR <30 mL/min/1.73 m2).
  9. Prior or ongoing medical condition or laboratory abnormality which in the Investigator's opinion may put the patient at significant risk, may confound the study results or may interfere significantly with the patient's participation in the study (please see below Note).
  10. History of or current drug or alcohol abuse or use of any tobacco/marijuana products/smoking.
  11. Known individual hypersensitivity to idebenone or to any of the ingredients/excipients of the study medication.
  12. Daytime ventilator assistance (defined as use of any assisted ventilation while awake).

Note: Patients who suffer from a severe, unstable condition including (but not limited to) cancer, auto-immune diseases, hematological diseases, metabolic disorders or immunodeficiencies, and who are at risk of an aggravation unrelated to the study condition, can only be included in the study if accepted in writing by the Sponsor's Senior Clinical Research Physician.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02814019

Contact: Jodi Wolff

  Hide Study Locations
United States, Alabama
University of Alabama Recruiting
Birmingham, Alabama, United States, 35233
Principal Investigator: Bradley Troxler, MD         
United States, Arizona
Banner University of Arizona Medical Center Recruiting
Tucson, Arizona, United States
Principal Investigator: Cori Daines, MD         
United States, Arkansas
Arkansas Children's Hospital Recruiting
Little Rock, Arkansas, United States, 72202
Principal Investigator: Vikki Stefans, MD         
United States, California
Not yet recruiting
Los Angeles, California, United States
Not yet recruiting
Sacramento, California, United States
Not yet recruiting
San Bernardino, California, United States
United States, District of Columbia
Not yet recruiting
Washington, DC, District of Columbia, United States
United States, Florida
Shriners Hospitals for Children-Tampa Recruiting
Tampa, Florida, United States
Principal Investigator: Marisia Couluris, MD         
United States, Georgia
Not yet recruiting
Atlanta, Georgia, United States
United States, Indiana
Indiana University Recruiting
Indianapolis, Indiana, United States
Principal Investigator: Marcia Felker, MD         
United States, Kansas
University of Kansas Recruiting
Fairway, Kansas, United States, 66160
Principal Investigator: Jeff Statland, MD         
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States
Principal Investigator: Thomas Crawford, MD         
United States, Massachusetts
Not yet recruiting
Boston, Massachusetts, United States
United States, Minnesota
Gillette Children's Specialty Healthcare Recruiting
Saint Paul, Minnesota, United States
Principal Investigator: Stephen A Smith, MD         
United States, North Carolina
Not yet recruiting
Charlotte, North Carolina, United States
United States, Ohio
Not yet recruiting
Cincinnati, Ohio, United States
United States, Pennsylvania
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104-1771
Principal Investigator: Oscar Mayer, MD         
United States, Tennessee
Wesley Neurology Clinic Recruiting
Memphis, Tennessee, United States
Principal Investigator: Tulio Bertorini, MD         
United States, Utah
University of Utah Recruiting
Salt Lake City, Utah, United States
Principal Investigator: Russell Butterfield, MD         
Not yet recruiting
Wien, Austria
University Hospital Leuven Recruiting
Leuven, Belgium, 3000
Principal Investigator: Gunnar Buyse, MD         
Centre de Référence Neuromusculaire, CHR Citadelle Recruiting
Liège, Belgium, 4000
Principal Investigator: Laurent Servais, MD         
Not yet recruiting
Lille, France
CHRU de Montpellier - Hôpital Gui de Chauliac Recruiting
Montpellier, France
Principal Investigator: Ulrike Walther-Louvier, MD         
Not yet recruiting
Paris, France
Not yet recruiting
Toulouse, France
Not yet recruiting
Essen, Germany
Not yet recruiting
Freiburg, Germany
Not yet recruiting
Köln, Germany
Not yet recruiting
Munich, Germany
Fondazione IRCCS Eugenio Medea Recruiting
Bosisio Parini, Italy
Principal Investigator: Maria Grazia Nadia D'Angelo, MD         
Not yet recruiting
Genova, Italy
Not yet recruiting
Messina, Italy
Not yet recruiting
Milano, Italy
U.O.C. Neuropsichiatria Infantile Recruiting
Roma, Italy
Principal Investigator: Eugenio Mercuri, MD         
Not yet recruiting
Leiden, Netherlands
Not yet recruiting
Nijmegen, Netherlands
Not yet recruiting
Barcelona, Spain
Not yet recruiting
Valencia, Spain
Not yet recruiting
Gothenburg, Sweden
Not yet recruiting
Karolinska, Sweden
Not yet recruiting
Basel, Switzerland
Not yet recruiting
Lausanne, Switzerland
United Kingdom
Not yet recruiting
Leeds, United Kingdom
Not yet recruiting
Newcastle, United Kingdom
Sponsors and Collaborators
Santhera Pharmaceuticals
  More Information

Responsible Party: Santhera Pharmaceuticals Identifier: NCT02814019     History of Changes
Other Study ID Numbers: SNT-III-012 
Study First Received: June 17, 2016
Last Updated: January 16, 2017

Keywords provided by Santhera Pharmaceuticals:
respiratory function in DMD

Additional relevant MeSH terms:
Muscular Dystrophy, Duchenne
Muscular Dystrophies
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Growth Substances
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on February 24, 2017